Last reviewed · How we verify

clonidine, levobupivacaine

University Hospital Dubrava · FDA-approved active Small molecule

Clonidine is an alpha-2 adrenergic agonist that reduces pain signaling, while levobupivacaine is a local anesthetic that blocks sodium channels to prevent nerve conduction.

Clonidine is an alpha-2 adrenergic agonist that reduces pain signaling, while levobupivacaine is a local anesthetic that blocks sodium channels to prevent nerve conduction. Used for Regional anesthesia and analgesia for surgical procedures, Postoperative pain management.

At a glance

Generic nameclonidine, levobupivacaine
Also known asclonidine [Catapres®, Boehringer Ingelheim, Germany], levobupivacaine [Chirocaine®, Abbott S.p.A., Italy]
SponsorUniversity Hospital Dubrava
Drug classLocal anesthetic with adjuvant alpha-2 agonist
TargetAlpha-2 adrenergic receptor (clonidine); voltage-gated sodium channels (levobupivacaine)
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhaseFDA-approved

Mechanism of action

This combination is used for regional anesthesia and analgesia. Clonidine enhances the analgesic effect of the local anesthetic by activating alpha-2 adrenergic receptors in the spinal cord and peripheral nerves, reducing pain transmission. Levobupivacaine, the active S-enantiomer of bupivacaine, blocks voltage-gated sodium channels in nerve fibers, preventing action potential propagation and producing local anesthesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: